CytomX Therapeutics Shares Owned By Institutions vs. Return On Asset
| CTMX Stock | USD 1.06 0.04 3.92% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.99 | 1.02 |
|
|
For CytomX Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CytomX Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CytomX Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CytomX Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CytomX Therapeutics over time as well as its relative position and ranking within its peers.
CytomX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.819 | Earnings Share 0.16 | Revenue Per Share 1.518 | Quarterly Revenue Growth 0.267 | Return On Assets 0.0233 |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CytomX Therapeutics Return On Asset vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CytomX Therapeutics's current stock value. Our valuation model uses many indicators to compare CytomX Therapeutics value to that of its competitors to determine the firm's financial worth. CytomX Therapeutics is rated second in shares owned by institutions category among its peers. It also is rated second in return on asset category among its peers . The ratio of Shares Owned By Institutions to Return On Asset for CytomX Therapeutics is about 2,816 . Return On Assets is likely to drop to -0.003 in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CytomX Therapeutics' earnings, one of the primary drivers of an investment's value.CytomX Return On Asset vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
CytomX Therapeutics |
| = | 65.62 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
CytomX Therapeutics |
| = | 0.0233 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CytomX Return On Asset Comparison
CytomX Therapeutics is currently under evaluation in return on asset category among its peers.
CytomX Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CytomX Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CytomX Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of CytomX Therapeutics' change in net profit over the period of time. It can combine multiple indicators of CytomX Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 95 K | 99.8 K | |
| Operating Income | -6.5 M | -6.8 M | |
| Income Before Tax | 3.3 M | 3.5 M | |
| Total Other Income Expense Net | 9.8 M | 10.3 M | |
| Net Loss | -569 K | -597.5 K | |
| Income Tax Expense | 3.9 M | 4.1 M | |
| Net Loss | -10.2 M | -10.7 M | |
| Net Loss | -104.3 M | -109.5 M | |
| Interest Income | 8.1 M | 4.1 M | |
| Net Interest Income | 8.1 M | 4.3 M | |
| Non Operating Income Net Other | 154.8 K | 147.1 K | |
| Change To Netincome | 15.1 M | 14.7 M | |
| Net Loss | (0.01) | (0.01) | |
| Income Quality | 98.48 | 103.40 | |
| Net Loss | (0.17) | (0.16) |
CytomX Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CytomX Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CytomX Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CytomX Therapeutics' important profitability drivers and their relationship over time.
Use CytomX Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.CytomX Therapeutics Pair Trading
CytomX Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CytomX Therapeutics position
In addition to having CytomX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Books Thematic Idea Now
Books
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.